DEF: XOMA sets 2026 AGM, seeks equity plan approvals

XOMA Royalty Corporation calls a May 21, 2026 virtual annual meeting to elect directors, ratify Deloitte, expand its long‑term incentive plan by 425,000 shares, adopt a 500,000‑share ESPP, and hold a Say‑on‑Pay vote.

Summary

• Annual Meeting: May 21, 2026 at 9:00 a.m. PT via live webcast; record date March 25, 2026 with 11,915,730 common shares outstanding.
• Board elections: Seven nominees standing for one‑year terms; independent chair structure maintained.
• Auditor: Proposal to ratify Deloitte & Touche LLP for FY2026; Deloitte has served since 2018.
• Equity Plan: Proposal to amend and restate the 2010 LTIP to add 425,000 shares and extend the plan term to March 16, 2036; estimated additional dilution ~2.5% of shares outstanding (inclusive of 5,003,000 shares issuable upon conversion of Series X Preferred Stock).
• Overhang & burn rate: Overhang ~25% as of Mar 1, 2026 (19% on a diluted basis); would rise to ~27% (20% diluted) if approved. Three‑year average burn rate 3.7% (2.6% on a diluted basis).
• ESPP: New 2026 Employee Stock Purchase Plan for 500,000 shares (~4% of OS as of Mar 1, 2026) with a 15% discount off the lower of offering or purchase date.
• Say‑on‑Pay: Advisory vote on 2025 NEO compensation.
• Executive updates: CFO transition—Thomas Burns stepped down Jan 12, 2026; Jeffrey Trigilio appointed CFO and Treasurer Jan 2026; Chief Legal Officer Maricel Montano appointed Aug 2025; CEO Owen Hughes appointed Jan 2024.
• Audit fees: 2025 total $1,703,525 (Audit $1,663,830; Tax $37,800; Other $1,895); 2024 total $1,536,013.
• Performance snapshot: Net income (loss) per Pay-Versus-Performance—2025: $31.7m; 2024: ($13.8m); 2023: ($40.8m). Cumulative TSR value of $144.51 on a $100 base through 2025.
• Ownership: Largest holders include BVF affiliates (21.8%), Morgan Stanley (14.3%), FMR (10.7%), and Vanguard (5.4%).
• Related‑party transactions: $3.0m arranger fees from Xeno in ESSA (Oct 2025) and Repare (closed Jan 28, 2026) acquisitions; a $5.9m bridge loan to Xeno repaid in Oct 2025; BVF held ~24–25% of ESSA/Repare pre‑deal.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive governance housekeeping with detailed transparency; dilution and elevated overhang temper enthusiasm but the plan design and burn‑rate discipline are constructive.

Positives

• Clear governance agenda with standard proposals (directors, auditor ratification, Say‑on‑Pay) and detailed rationale.
• Measured equity usage: three‑year average burn rate of 3.7% (2.6% diluted), trending lower after 2023 as grants shifted from options to PSUs.
• Equity plan best practices: no repricing, no liberal share recycling, no dividends on unvested awards, 10‑year max term on options/SARs, and a $750,000 annual cap on non‑employee director compensation.
• New ESPP (500,000 shares) enhances employee alignment and retention with a 15% discount.
• Audit continuity with Deloitte & Touche LLP; 2025 audit fees detailed and pre‑approved per policy.
• Improving performance indicators in Pay‑Versus‑Performance: 2025 net income of $31.7m and cumulative TSR of $144.51 since 2023 base.
• Board independence maintained with an independent chair and 6 of 7 nominees deemed independent under Nasdaq rules.

Negatives

• Incremental dilution from the LTIP increase (425,000 shares, ~2.5% inclusive of preferred share conversion) and ESPP (500,000 shares, ~4% of OS).
• Aggregate equity overhang remains elevated at ~25% (would rise to ~27% if the LTIP increase is approved), which can pressure future per‑share metrics.
• A portion of outstanding options (696,267) were underwater as of Mar 1, 2026 (exercise price > $25.53), reducing motivational value without re‑granting.
• Related‑party optics: arranger fees and bridge financing connected to Xeno transactions where a major stockholder (BVF) held sizable stakes in the targets.

Risks

• Shareholder dilution from adding 425,000 LTIP shares (~2.5% inclusive of potential Series X Preferred conversion) and adopting a 500,000‑share ESPP (~4% of OS).
• Equity overhang would increase to ~27% (20% on a diluted basis) if the LTIP proposal is approved; excluding 696,267 underwater options, overhang would still be ~24% (18% diluted).
• Potential perceived conflicts from related‑party aspects of Xeno/ESSA and Xeno/Repare transactions involving arranger fees and a short‑term loan, while a >5% holder (BVF) owned ~24–25% of ESSA/Repare.
• Broker non‑votes may impact outcomes on non‑routine proposals if beneficial owners do not direct votes.

Future Outlook

Management expects the 425,000‑share LTIP increase to fund approximately one year of equity grants at the current burn rate and plans to file Form S‑8 in Q2/Q3 2026 for both the LTIP increase and the ESPP if approved. Beginning in 2026, annual equity awards will be granted in Q1 each year to better align grants with performance cycles.

Management Comments

• All nominees possess the skills and experience to effectively oversee strategy and execution; annual elections align with best practices.
• Deloitte & Touche was selected after a robust annual review of independence, performance, quality, and fees.
• The LTIP amendment is reasonable, adds only ~2.5% incremental dilution (inclusive of preferred conversion), and extends the plan for 10 years; based on current burn rate, the new pool should last about one year.
• The 2026 ESPP is an important tool to attract and retain talent by offering employees the chance to become stockholders at favorable prices, aligning interests with stockholders.
• Executive compensation emphasizes pay‑for‑performance through incentive programs that align management’s interests with long‑term stockholder value.

Industry Context

StockSavvy.ai notes that equity compensation remains a primary tool for talent retention across small-cap biotech and royalty platforms, where overhangs in the 20–40% range and 3–6% burn rates are common. XOMA’s proposed pool size, governance guardrails (no repricing, no liberal recycling), and a three-year average burn rate of 3.7% are broadly consistent with sector norms among biotech developers and royalty aggregators.

Comparison to Industry Standards

• StockSavvy.ai comparison: XOMA’s three‑year average burn rate (3.7%) is at or below typical small/mid‑cap biotech levels (often ~4–6%), suggesting disciplined equity usage relative to peers such as Mirati, Exelixis, and Halozyme during growth cycles.
• Equity overhang near ~25–27% (pre/post proposal) is within the common 20–40% range observed in small‑cap biotech; royalty platforms like Royalty Pharma and DRI Healthcare often run lower headline overhangs due to scale but still rely on equity for alignment.
• Governance provisions (no repricing, no liberal share recycling, 10‑year option/SAR term, director pay cap) align with best‑practice frameworks endorsed by proxy advisors, comparable to policies adopted by peers including Exelixis and Halozyme.

Management Changes

Corporate Governance

Related Party Transactions

• October 2025: Acted as structuring agent for Xeno’s acquisition of ESSA; received a $3.0m arranger fee (received Oct 2025) and provided a $5.9m bridge loan to Xeno that was repaid in Oct 2025; BVF (a >5% XOMA holder) owned ~24.7% of ESSA pre‑deal.
• January 28, 2026: Acted as structuring agent for Xeno’s acquisition of Repare; received a $3.0m arranger fee in Jan 2026; BVF (a >5% XOMA holder) owned ~24.0% of Repare pre‑deal.

Stakeholder Impact

• Shareholders: Potential dilution from adding 425,000 LTIP shares (~2.5% inclusive of preferred conversion) and adopting a 500,000‑share ESPP (~4% of OS); governance protections mitigate risk.
• Employees: Expanded access to equity incentives and a discounted ESPP to enhance retention and alignment.
• Customers/Partners: Continuity in auditor oversight and risk governance; no direct operational impact disclosed.
• Creditors: No new indebtedness disclosed; related‑party bridge loan to Xeno was repaid in 2025.
• Directors and Officers: Clear compensation philosophy and clawback policy; annual elections maintain accountability.

Next Steps

• Vote by internet/phone by May 20, 2026 (May 18 for 401(k) plan holders) or live during the May 21, 2026 webcast meeting.
• If Proposals 3 and 4 pass, file Form S‑8 in Q2/Q3 2026 to register additional LTIP and ESPP shares.
• Assuming approval, begin annual Q1 equity grant cadence starting in 2026.
• Finalize auditor engagement for FY2026 upon ratification.
• Publish final vote results via Form 8‑K within four business days after the meeting.

Key Dates

Recommendation

The agenda is largely standard governance with transparent equity plan terms and prudent burn‑rate trends, balanced by elevated overhang and incremental dilution. Without new operating or financial guidance, a neutral Hold is appropriate pending business updates outside this proxy.

Keywords

XOMA Royalty Corporation, proxy statement, DEF 14A, annual meeting, equity incentive plan, 2010 Long Term Incentive Plan, ESPP, Deloitte & Touche, Say-on-Pay, biotech royalty, overhang, burn rate, Series X Preferred Stock, BVF Partners, related party transactions